5 Key Takeaways

• 1

  Corneal cross-linking (CXL) is a standard of care for keratoconus and ectasia, approved by the FDA since 2015.

• 2

  Insurance reimbursement for CXL is often limited by the definition of medical necessity, requiring specific documentation.

• 3

  Patients must meet criteria including age, corneal thickness, and visual acuity to qualify for CXL.

• 4

  Contraindications for CXL include corneal scarring, severe ocular surface disease, and certain infections.

• 5

  Practitioners should confirm diagnosis and contraindications before referring patients for CXL and advise on potential insurance coverage gaps.